<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682403-A2" country="EP" doc-number="2682403" kind="A2" date="20140108" family-id="41265093" file-reference-id="318267" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586292" ucid="EP-2682403-A2"><document-id><country>EP</country><doc-number>2682403</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13179392-A" is-representative="NO"><document-id mxw-id="PAPP154848484" load-source="docdb" format="epo"><country>EP</country><doc-number>13179392</doc-number><kind>A</kind><date>20090508</date><lang>EN</lang></document-id><document-id mxw-id="PAPP184034290" load-source="docdb" format="original"><country>EP</country><doc-number>13179392.9</doc-number><date>20090508</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140547085" ucid="EP-09742466-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>09742466</doc-number><kind>A</kind><date>20090508</date></document-id></priority-claim><priority-claim mxw-id="PPC140556554" ucid="US-5145908-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>5145908</doc-number><kind>P</kind><date>20080508</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2128535713" load-source="docdb">C12N  15/82        20060101ALI20141126BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2128537157" load-source="docdb">C07K  14/415       20060101AFI20141126BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2102482387" load-source="docdb" scheme="CPC">C07K  14/415       20130101 LI20150127BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2102482652" load-source="docdb" scheme="CPC">C12N  15/8281      20130101 FI20150127BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132363509" lang="DE" load-source="patent-office">Gen und Verfahren zur Erhöhung der Krankheitsresistenz bei Pflanzen</invention-title><invention-title mxw-id="PT132363510" lang="EN" load-source="patent-office">Genes and methods for increasing disease resistance in plants</invention-title><invention-title mxw-id="PT132363511" lang="FR" load-source="patent-office">Gène et procédé pour augmenter la résistance aux maladies de plantes</invention-title><citations><patent-citations><patcit mxw-id="PCIT242945927" load-source="docdb" ucid="US-20040143874-A1"><document-id format="epo"><country>US</country><doc-number>20040143874</doc-number><kind>A1</kind><date>20040722</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945928" load-source="docdb" ucid="US-20040253717-A1"><document-id format="epo"><country>US</country><doc-number>20040253717</doc-number><kind>A1</kind><date>20041216</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945930" load-source="docdb" ucid="US-20070266457-A1"><document-id format="epo"><country>US</country><doc-number>20070266457</doc-number><kind>A1</kind><date>20071115</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945929" load-source="docdb" ucid="US-20070271627-A1"><document-id format="epo"><country>US</country><doc-number>20070271627</doc-number><kind>A1</kind><date>20071122</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945916" load-source="docdb" ucid="US-4987071-A"><document-id format="epo"><country>US</country><doc-number>4987071</doc-number><kind>A</kind><date>19910122</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945917" load-source="docdb" ucid="US-5559021-A"><document-id format="epo"><country>US</country><doc-number>5559021</doc-number><kind>A</kind><date>19960924</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945919" load-source="docdb" ucid="US-5580967-A"><document-id format="epo"><country>US</country><doc-number>5580967</doc-number><kind>A</kind><date>19961203</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945918" load-source="docdb" ucid="US-5583032-A"><document-id format="epo"><country>US</country><doc-number>5583032</doc-number><kind>A</kind><date>19961210</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945922" load-source="docdb" ucid="US-5589367-A"><document-id format="epo"><country>US</country><doc-number>5589367</doc-number><kind>A</kind><date>19961231</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945921" load-source="docdb" ucid="US-5591601-A"><document-id format="epo"><country>US</country><doc-number>5591601</doc-number><kind>A</kind><date>19970107</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945920" load-source="docdb" ucid="US-5595877-A"><document-id format="epo"><country>US</country><doc-number>5595877</doc-number><kind>A</kind><date>19970121</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945923" load-source="docdb" ucid="US-5622854-A"><document-id format="epo"><country>US</country><doc-number>5622854</doc-number><kind>A</kind><date>19970422</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945924" load-source="docdb" ucid="US-6132970-A"><document-id format="epo"><country>US</country><doc-number>6132970</doc-number><kind>A</kind><date>20001017</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945925" load-source="docdb" ucid="US-6563026-B2"><document-id format="epo"><country>US</country><doc-number>6563026</doc-number><kind>B2</kind><date>20030513</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945926" load-source="docdb" ucid="US-6613960-B1"><document-id format="epo"><country>US</country><doc-number>6613960</doc-number><kind>B1</kind><date>20030902</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945931" load-source="docdb" ucid="WO-2000052168-A1"><document-id format="epo"><country>WO</country><doc-number>2000052168</doc-number><kind>A1</kind><date>20000908</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242945932" load-source="docdb" ucid="WO-2001059086-A2"><document-id format="epo"><country>WO</country><doc-number>2001059086</doc-number><kind>A2</kind><date>20010816</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>ALTSCHUL ET AL., NUCLEIC ACID RES., vol. 25, 1997, pages 3389 - 3402</text><sources><source mxw-id="PNPL56389696" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>AUSUBEL ET AL.,: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1988, GREENE PUBLISHING ASSOCIATES AND WILEY-INTERSCIENCE</text><sources><source mxw-id="PNPL56389697" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>AUSUBEL ET AL.,: "SHORT PROTOCOLS IN MOLECULAR BIOLOGY: A COMPENDIUM OF METHODS FROM CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 5th ed.,", vol. 1-2, 2002, JOHN WILEY &amp; SONS, INC.</text><sources><source mxw-id="PNPL56389698" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BEAUCAGE; CARUTHERS, TETRA. LETTS., vol. 22, 1981, pages 1859 - 1862</text><sources><source mxw-id="PNPL56389699" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BECHTOLD ET AL., C. R. ACAD. SCI. PARIS, vol. 316, 1993, pages 1194 - 1199</text><sources><source mxw-id="PNPL56389700" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BENT ET AL., MOL. GEN. GENET, vol. 204, 1986, pages 383 - 396</text><sources><source mxw-id="PNPL56389701" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BROOTHAERTS ET AL., NATURE, vol. 433, 2005, pages 629 - 633</text><sources><source mxw-id="PNPL56389702" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CUBERO; GRAHAM, PHYTOPATHOLOGY, vol. 95, 2005, pages 1333 - 1340</text><sources><source mxw-id="PNPL56389703" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DANGL; JONES, NATURE, vol. 411, 2001, pages 826 - 33</text><sources><source mxw-id="PNPL56389704" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DIEFFENBACH; DVEKSLER: "PCR PRIMER: A LABORATORY MANUAL, 2nd ed.,", 2003, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56389705" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DURRANT; DONG, ANNU. REV. PHYTOPATHOL., vol. 42, 2004, pages 185 - 209</text><sources><source mxw-id="PNPL56389706" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GREEN ET AL.,: "GENOME ANALYSIS: A LABORATORY MANUAL", vol. 1-2, 1997, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56389707" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HEATH, PLANT MOLECULAR BIOLOGY, vol. 44, 2000, pages 321 - 34</text><sources><source mxw-id="PNPL56389708" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HUANG, X.; MADAN, A.: "CAP3: A DNA sequence assembly program", GENOME RES., vol. 9, 1999, pages 868 - 877</text><sources><source mxw-id="PNPL75870674" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>INNIS ET AL.: "PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS", 1990, ACADEMIC PRESS</text><sources><source mxw-id="PNPL56389710" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KLEIN ET AL., BIOTECHNOLOGY, vol. 4, 1993, pages 583 - 590</text><sources><source mxw-id="PNPL56389711" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KLEIN ET AL., NATURE, vol. 327, 1987, pages 70 - 73</text><sources><source mxw-id="PNPL56389712" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KOSACK; JONES, ANNU. REV. PLANT PHYSIOL. PLANT MOLEC. BIOL., vol. 48, 1997, pages 575 - 607</text><sources><source mxw-id="PNPL56389713" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>L. W. TIMMER, STEPHEN MICHAEL GARNSEY, AND J. H. GRAHAM: "COMPENDIUM OF CITRUS DISEASES", APS PRESS</text><sources><source mxw-id="PNPL56389714" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>LORZ ET AL., MOL. GENET, vol. 199, 1985, pages 179 - 182</text><sources><source mxw-id="PNPL56389715" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MALIGA ET AL.,: "METHODS IN PLANT MOLECULAR BIOLOGY: A LABORATORY COURSE MANUAL", 1995, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56389716" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MATTEUCCI; CARUTHERS, J. AM. CHEM. SOC., vol. 103, 1981, pages 3185</text><sources><source mxw-id="PNPL56389717" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NAGEL ET AL., MICROBIOL LETT, vol. 67, 1990, pages 325</text><sources><source mxw-id="PNPL56389718" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PASZOWSKI ET AL., EMBO J., vol. 3, 1984, pages 2717 - 2722</text><sources><source mxw-id="PNPL56389719" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAGI ET AL., PLANT CELL REP., vol. 13, 1994, pages 26 15 - 286</text><sources><source mxw-id="PNPL56389720" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK AND RUSSEL: "MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed.", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56389721" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed.,", 1989, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56389722" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SHIRASU; SCHULZE-LEFERT, PLANT MOL. BIOL, vol. 44, 2000, pages 371 - 385</text><sources><source mxw-id="PNPL56389723" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>STECKEL; FALCIANI, GENOME RESEARCH, vol. 10, 2000, pages 2055 - 2061</text><sources><source mxw-id="PNPL56389724" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SUN-MI ET AL., BIOCHEMICAL JOURNAL, vol. 383, 2004, pages 53 - 61</text><sources><source mxw-id="PNPL56389725" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WESTERINK ET AL., MOL. MICROBIOL., vol. 54, 2004, pages 533 - 545</text><sources><source mxw-id="PNPL56389726" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ZOLLER; SMITH, NUCLEIC ACID RES., vol. 10, 1982, pages 6487 - 500</text><sources><source mxw-id="PNPL56389727" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13179392-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13179392</doc-number><kind>A</kind><date>20090508</date></document-id></child-doc><parent-doc ucid="EP-09742466.7"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>09742466.7</doc-number><date>20090508</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919512086" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ALELLYX APPLIED GENOMICS</last-name><address><country>BR</country></address></addressbook></applicant><applicant mxw-id="PPAR919503920" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ALELLYX APPLIED GENOMICS</last-name></addressbook></applicant><applicant mxw-id="PPAR919015454" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Alellyx Applied Genomics</last-name><iid>101148013</iid><address><street>Rua James Clerk Maxwell 320 Techno Park (Rod. Anhanguera Km 104)</street><city>13069-380 Campinas Sao Paulo</city><country>BR</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919537321" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SILVA ANA CLAUDIA RASERA</last-name><address><country>BR</country></address></addressbook></inventor><inventor mxw-id="PPAR919530980" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SILVA, ANA CLAUDIA RASERA</last-name></addressbook></inventor><inventor mxw-id="PPAR919012094" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SILVA, ANA CLAUDIA RASERA</last-name><address><street>c/o Allelyx Applied Genetics Rua James Clerk Maxwell 320 Techno Park (Rod. Anhanguera Km 104)</street><city>13069-380 Campinas Sao Paulo</city><country>BR</country></address></addressbook></inventor><inventor mxw-id="PPAR919532740" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MONGE GUSTAVO ADOLFO ASTUA</last-name><address><country>BR</country></address></addressbook></inventor><inventor mxw-id="PPAR919529831" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MONGE, GUSTAVO ADOLFO ASTUA</last-name></addressbook></inventor><inventor mxw-id="PPAR919014019" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MONGE, GUSTAVO ADOLFO ASTUA</last-name><address><street>c/o Allelyx Applied Genomics Rua James Clerk Maxwell 320 Techno Park (Rod. Anhanguera Km 104)</street><city>13069-380 Campinas Sao Paulo</city><country>BR</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919012855" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>von Kreisler Selting Werner</last-name><iid>101166970</iid><address><street>Deichmannhaus am Dom Bahnhofsvorplatz 1</street><city>50667 Köln</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549849169" load-source="docdb">AT</country><country mxw-id="DS549836442" load-source="docdb">BE</country><country mxw-id="DS549759222" load-source="docdb">BG</country><country mxw-id="DS549758799" load-source="docdb">CH</country><country mxw-id="DS549836347" load-source="docdb">CY</country><country mxw-id="DS549849334" load-source="docdb">CZ</country><country mxw-id="DS549836443" load-source="docdb">DE</country><country mxw-id="DS549836348" load-source="docdb">DK</country><country mxw-id="DS549836349" load-source="docdb">EE</country><country mxw-id="DS549914186" load-source="docdb">ES</country><country mxw-id="DS549759223" load-source="docdb">FI</country><country mxw-id="DS549759224" load-source="docdb">FR</country><country mxw-id="DS549836444" load-source="docdb">GB</country><country mxw-id="DS549836358" load-source="docdb">GR</country><country mxw-id="DS549836445" load-source="docdb">HR</country><country mxw-id="DS549849335" load-source="docdb">HU</country><country mxw-id="DS549758800" load-source="docdb">IE</country><country mxw-id="DS549836450" load-source="docdb">IS</country><country mxw-id="DS549759229" load-source="docdb">IT</country><country mxw-id="DS549836359" load-source="docdb">LI</country><country mxw-id="DS549835337" load-source="docdb">LT</country><country mxw-id="DS549849336" load-source="docdb">LU</country><country mxw-id="DS549835346" load-source="docdb">LV</country><country mxw-id="DS549835347" load-source="docdb">MC</country><country mxw-id="DS549768810" load-source="docdb">MK</country><country mxw-id="DS549768811" load-source="docdb">MT</country><country mxw-id="DS549759230" load-source="docdb">NL</country><country mxw-id="DS549914187" load-source="docdb">NO</country><country mxw-id="DS549758805" load-source="docdb">PL</country><country mxw-id="DS549768812" load-source="docdb">PT</country><country mxw-id="DS549759231" load-source="docdb">RO</country><country mxw-id="DS549758806" load-source="docdb">SE</country><country mxw-id="DS549768829" load-source="docdb">SI</country><country mxw-id="DS549914188" load-source="docdb">SK</country><country mxw-id="DS549835348" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128674130" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention relates to the regulation of the natural defense system of plants through the introduction of foreign/native genes into plant cells, preferably into their genomes. More specifically, the methods relate to increasing citrus plant disease resistance by over-expressing genes involved in the innate plant defense system.</p></abstract><abstract mxw-id="PA128738630" lang="EN" source="EPO" load-source="docdb"><p>The present invention relates to the regulation of the natural defense system of plants through the introduction of foreign/native genes into plant cells, preferably into their genomes. More specifically, the methods relate to increasing citrus plant disease resistance by over-expressing genes involved in the innate plant defense system.</p></abstract><description mxw-id="PDES63960118" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>CROSS-REFERENCE TO RELATED APPLICATION</u></b></heading><p id="p0001" num="0001">This application claims priority to <patcit id="pcit0001" dnum="US61051459A"><text>U. S. Provisional Application No. 61/051,459, filed May 8, 2008</text></patcit>.</p><heading id="h0002"><b><u>FIELD OF THE INVENTION</u></b></heading><p id="p0002" num="0002">The present invention relates to the field of molecular biology and the regulation of the natural defense system of plants through the introduction of foreign/native genes into plant cells, preferably into their genomes. More specifically, the method relates to increasing citrus plant disease resistance by overexpressing genes involved in the innate plant defense system. The invention also relates to such genes.</p><heading id="h0003"><b><u>INTRODUCTION</u></b></heading><p id="p0003" num="0003">In nature, plants and animals are in permanent contact with a widely diverse array of microorganisms, though seldom does this association result in disease. This is due mainly to the existence of defense systems which, in the case of plants, lack the adaptive immune response common in the animal kingdom.</p><p id="p0004" num="0004">The ability of a plant to recognize a pathogen and activate an effective defense is often controlled by the interaction (direct or indirect) between the products of a plant resistance gene and a pathogen avirulence gene. <nplcit id="ncit0001" npl-type="s"><text>Dangl and Jones, 2001, Nature 411, 826-33</text></nplcit>. As a consequence of this gene-for-gene interaction, the newly infected tissue may exhibit ion fluxes, the production of reactive oxygen species, salicylic acid (SA), nitric oxide, and increased expression of defense-associated genes, including those encoding pathogenesis-related (PR) proteins. <nplcit id="ncit0002" npl-type="s"><text>Durrant and Dong, 2004, Annu. Rev. Phytopathol. 2004. 42:185-209</text></nplcit>. In addition, the cells surrounding the site(s) of pathogen entry usually undergo apoptotic-like cell death, thereby forming the necrotic lesions characteristic of the hypersensitive response (HR). <nplcit id="ncit0003" npl-type="s"><text>Heath, 2000, Plant Molecular Biology 44: 321-34</text></nplcit>.</p><p id="p0005" num="0005">To date, several plant resistance genes (R genes) have been cloned and based on the structure of the proteins they encode, the genes are divided into several groups (Hammond-<nplcit id="ncit0004" npl-type="s"><text>Kosack<!-- EPO <DP n="2"> --> and Jones, 1997, Annu. Rev. Plant Physiol. Plant Molec. Biol. 48, 575-607</text></nplcit>). Most R genes encode cytoplasmic NB-LRR proteins, containing a nucleotide binding site (NB) and leucine-rich repeats (LRR). This group consists of genes encoding CC-NB-LRR proteins, containing a coiled-coil domain and genes that encode proteins that have a domain similar to mammalian Toll and interleukin (IL) receptors, the so-called TIR-NB-LRR proteins (Hammond-Kosack and Jones, 1997, supra).</p><p id="p0006" num="0006">Using such specific resistance genes in breeding programs for durable resistance is problematic since pathogens easily circumvent recognition by mutations in their avirulence factors, thereby preventing induction of active defense (<nplcit id="ncit0005" npl-type="s"><text>Westerink et al., 2004, Mol. Microbiol. 54, 533-545</text></nplcit>). Similarity among resistance proteins (R proteins) suggests the existence of common resistance pathways (<nplcit id="ncit0006" npl-type="s"><text>Shirasu and Schulze-Lefert, 2000, Plant Mol. Biol. 44, 371-385</text></nplcit>). Therefore, identification of additional genes required for resistance not only provides information on how such signaling pathways function but might also enable us to identify genes that play a more general role in resistance.</p><p id="p0007" num="0007">Despite the increasing information about disease resistance pathways, there is still a need to identify genes and proteins that can be used to create plants with durable, broad range disease resistance. It is an object of the invention to provide such nucleic acids, proteins and methods for creating plants, especially plants belonging to the family Rutaceae, with enhanced disease resistance.</p><heading id="h0004"><b><u>SUMMARY OF THE INVENTION</u></b></heading><p id="p0008" num="0008">In one aspect, the invention provides an isolated nucleic acid sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 14-26.</p><p id="p0009" num="0009">In another aspect, the invention provides a construct comprising a nucleotide sequence set forth in SEQ ID NO: 1-13. In one embodiment, the construct comprises a nucleotide sequence having at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with a nucleotide sequence set forth in SEQ ID NO: 1-13. In one embodiment, a nucleotide sequence is operatively linked to a promoter which functions in plants and said promoter expresses a polypeptide sequence set forth in SEQ ID NO: 14-26. In a further embodiment, the promoter is selected from a CaMV 35S promoter, polyubiquitin promoter, tissue specific<!-- EPO <DP n="3"> --> promoter, and a tissue preferred promoter. In another embodiment, a plant cell comprises the construct.</p><p id="p0010" num="0010">In another aspect, the invention provides a method for increasing resistance to citrus canker disease in a plant or cell, comprising overexpressing at least one nucleotide sequence set forth in SEQ ID NO: 1-13. In one embodiment, a plant, plant cell, seed, or fruit is produced by the method.</p><p id="p0011" num="0011">In another aspect, the invention provides a method for increasing resistance to citrus canker disease in a plant or cell, comprising (a) transforming a plant or cell with a construct comprising at least one nucleotide sequence set forth in SEQ ID NO: 1-13, operably linked to a promoter active in plant cells; (b) regenerating a plant from said transformed plant or cell; and (c) selecting a plant or cell that has increased resistance to citrus canker disease relative to a control plant. In one embodiment, the promoter is operably linked to an enhancer. In another embodiment, the promoter is a constitutive promoter or a tissue-specific promoter. In a further embodiment, the tissue specific promoter is a xylem-specific promoter, phloem-specific promoter, or a xylem/phloem-specific promoter. In another embodiment, the plant is a member of the Rutaceae family. In a further embodiment, the plant is selected from the genera of <i>Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia</i>, and <i>Eremocitrus.</i> In another embodiment, a plant. In another embodiment, a plant cell, seed, or fruit is produced by the method.</p><p id="p0012" num="0012">In another aspect, the invention provides a transgenic plant having incorporated into its genome a nucleotide sequence that encodes a disease resistance polypeptide set forth in SEQ ID NO: 14-26. In one embodiment, the polypeptide is encoded by a nucleotide sequence set forth in SEQ ID NO: 1-13. In a further embodiment, progeny, fruit, or seed of the plant comprise said nucleotide sequence.</p><heading id="h0005"><b><u>BRIEF DESCRIPTION OF THE DRAWINGS</u></b></heading><p id="p0013" num="0013"><figref idrefs="f0001">Figure 1</figref>. In silico expression profiles of a selected sample of genes identified in cDNA libraries constructed from citrus leaf tissue previously challenged with <i>Xanthomonas axonopodis</i> pv citri (A-12h, A-24h e A-48h) e <i>Xanthomonas axonopodis</i> pv aurantifolii (C-12h, C-24h e C-48h).<!-- EPO <DP n="4"> --></p><p id="p0014" num="0014"><figref idrefs="f0002">Figure 2</figref>. Differential expression of selected <i>deg</i> genes in citrus plants challenged with <i>Xanthomonas axonopodis</i> pv citri (A-12, A-24 e A-48) e <i>Xanthomonas axonopodis</i> pv aurantifolii (C-12h, C-24h e C-48h).</p><p id="p0015" num="0015"><figref idrefs="f0003">Figure 3</figref>. Schematic representation of pr35S(2x)-CaMV::ahas::35SpolyA | pr35S-CaMV::deg::NOSpolyA vectors.</p><p id="p0016" num="0016"><figref idrefs="f0004">Figure 4</figref>. Diagrammatic scale illustrating the development of citrus canker lesions on sweet orange leaves artificially inoculated with a bacterial suspension of <i>Xanthomonas axonopodis</i> pv citri.</p><p id="p0017" num="0017"><figref idrefs="f0005">Figure 5</figref>. Disease severity in selected pr35S-CaMV::deg::NOSpolyA events and control variety Pineapple (C).</p><p id="p0018" num="0018"><figref idrefs="f0006">Figure 6</figref>. Differential growth rate of the citrus canker bacterium in citrus plants carrying the pr35S-CaMV::deg::NOSpolyA constructs and control variety Pineapple (C).</p><p id="p0019" num="0019"><figref idrefs="f0007">Figure 7</figref>. Transgene expression levels in selected events carrying the pr35S-CaMV::deg::NOSpolyA constructs and control variety Pineapple (C).</p><heading id="h0006"><b><u>BRIEF DESCRIPTION OF THE SEQUENCES IN SEQUENCE LISTING</u></b></heading><p id="p0020" num="0020">SEQ ID NO: 1 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to a glycine-rich protein belonging to the shepherin family of antimicrobial peptides.</p><p id="p0021" num="0021">SEQ ID NO: 2 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme of the peroxidase family.</p><p id="p0022" num="0022">SEQ ID NO: 3 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an antimicrobial peptide of the snakin family.</p><p id="p0023" num="0023">SEQ ID NO: 4 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme with phosphatase activity.</p><p id="p0024" num="0024">SEQ ID NO: 5 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme with E3 ligase activity.</p><p id="p0025" num="0025">SEQ ID NO: 6 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme with E3 ligase activity.<!-- EPO <DP n="5"> --></p><p id="p0026" num="0026">SEQ ID NO: 7 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme with asparagine synthase activity.</p><p id="p0027" num="0027">SEQ ID NO: 8 <i>Citrus senensis</i> DNA sequence encoding a polypeptide that may be involved in the natural defense system of plants.</p><p id="p0028" num="0028">SEQ ID NO: 9 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to a transcription factor of the Ethylene Responsive Element Binding Protein family.</p><p id="p0029" num="0029">SEQ ID NO: 10 <i>Citrus senensis</i> DNA sequence encoding a polypeptide that may be involved in the natural defense system of plants.</p><p id="p0030" num="0030">SEQ ID NO: 11 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to a theoretical protein of yet unknown function; however, it has domains similar to those found in transcription factor of the FRIGIDA family.</p><p id="p0031" num="0031">SEQ ID NO: 12 <i>Citrus senensis</i> DNA sequence encoding a polypeptide that may be involved in the natural defense system of plants.</p><p id="p0032" num="0032">SEQ ID NO: 13 <i>Citrus senensis</i> DNA sequence encoding a polypeptide with similarity to an enzyme with transferase activity.</p><p id="p0033" num="0033">SEQ ID NO: 14 predicted protein sequence for SEQ ID NO: 1.</p><p id="p0034" num="0034">SEQ ID NO: 15 predicted protein sequence for SEQ ID NO: 2.</p><p id="p0035" num="0035">SEQ ID NO: 16 predicted protein sequence for SEQ ID NO: 3.</p><p id="p0036" num="0036">SEQ ID NO: 17 predicted protein sequence for SEQ ID NO: 4.</p><p id="p0037" num="0037">SEQ ID NO: 18 predicted protein sequence for SEQ ID NO: 5.</p><p id="p0038" num="0038">SEQ ID NO: 19 predicted protein sequence for SEQ ID NO: 6.</p><p id="p0039" num="0039">SEQ ID NO: 20 predicted protein sequence for SEQ ID NO: 7.</p><p id="p0040" num="0040">SEQ ID NO: 21 predicted protein sequence for SEQ ID NO: 8.</p><p id="p0041" num="0041">SEQ ID NO: 22 predicted protein sequence for SEQ ID NO: 9.</p><p id="p0042" num="0042">SEQ ID NO: 23 predicted protein sequence for SEQ ID NO: 10.</p><p id="p0043" num="0043">SEQ ID NO: 24 predicted protein sequence for SEQ ID NO: 11.</p><p id="p0044" num="0044">SEQ ID NO: 25 predicted protein sequence for SEQ ID NO: 12.<!-- EPO <DP n="6"> --></p><p id="p0045" num="0045">SEQ ID NO: 26 predicted protein sequence for SEQ ID NO: 13.</p><heading id="h0007"><b><u>DETAILED DESCRIPTION OF THE INVENTION</u></b></heading><p id="p0046" num="0046">The present invention relates to methods of regulating the natural defense system of plants through the introduction of foreign/native genes into plant cells, preferably into their genomes. More specifically, the methods relate to increasing plant disease resistance by overexpressing genes involved in the innate plant defense system.</p><p id="p0047" num="0047">The present inventors used expressed sequence tag libraries (EST's), in combination with challenging citrus plants with avirulent and virulent bacterial pathogens, to identify genes involved in the effector-dependent hypersensitive reaction (HR) and disease resistance. A total of 2868 putative genes were found to be differentially expressed in citrus plants challenged with an avirulent pathogen, as compared to those inoculated with a virulent bacterial strain. Among those, 29 genes were selected to test their individual potential to confer resistance to citrus plants against the most common bacterial pathogens of citrus.</p><p id="p0048" num="0048">The inventors found that the overexpression of 13 of these genes conferred enhanced resistance to citrus plants against <i>Xanthomonas axonopodis</i> pv. citri, the causal agent of citrus canker disease. These 13 genes, as denoted in SEQ ID NOs: 1-13, are related in that each encodes a protein involved in plant defense.</p><p id="p0049" num="0049">All technical terms used herein are terms commonly used in biochemistry, molecular biology and agriculture, and can be understood by one of ordinary skill in the art to which this invention belongs. Those technical terms can be found in: <nplcit id="ncit0007" npl-type="b"><text>MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed., vol. 1-3, ed. Sambrook and Russel, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001</text></nplcit>; <nplcit id="ncit0008" npl-type="b"><text>CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, ed. Ausubel et al., Greene Publishing Associates and Wiley-Interscience, New York, 1988</text></nplcit> (with periodic updates); <nplcit id="ncit0009" npl-type="b"><text>SHORT PROTOCOLS IN MOLECULAR BIOLOGY: A COMPENDIUM OF METHODS FROM CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 5th ed., vol. 1-2, ed. Ausubel et al., John Wiley &amp; Sons, Inc., 2002</text></nplcit>; <nplcit id="ncit0010" npl-type="b"><text>GENOME ANALYSIS: A LABORATORY MANUAL, vol. 1-2, ed. Green et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1997</text></nplcit>. Methodology involving plant biology techniques is described herein and is described in detail in treatises such as <nplcit id="ncit0011" npl-type="b"><text>METHODS IN PLANT MOLECULAR BIOLOGY: A LABORATORY COURSE MANUAL, ed. Maliga et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1995</text></nplcit>. Various techniques using PCR are described, e.g., in <nplcit id="ncit0012" npl-type="b"><text>Innis et al., PCR PROTOCOLS: A GUIDE TO<!-- EPO <DP n="7"> --> METHODS AND APPLICATIONS, Academic Press, San Diego, 1990</text></nplcit> and in <nplcit id="ncit0013" npl-type="b"><text>Dieffenbach and Dveksler, PCR PRIMER: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2003</text></nplcit>. PCR-primer pairs can be derived from known sequences by known techniques such as using computer programs intended for that purpose, e.g., Primer, Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge, MA. Methods for chemical synthesis of nucleic acids are discussed, for example, in <nplcit id="ncit0014" npl-type="s"><text>Beaucage and Caruthers, Tetra. Letts. 22:1859-1862 (1981</text></nplcit>), and <nplcit id="ncit0015" npl-type="s"><text>Matteucci and Caruthers, J. Am. Chem. Soc. 103:3185 (1981</text></nplcit>).</p><p id="p0050" num="0050">Restriction enzyme digestions, phosphorylations, ligations and transformations were done as described in <nplcit id="ncit0016" npl-type="b"><text>Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. (1989), Cold Spring Harbor Laboratory Press</text></nplcit>. All reagents and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), Invitrogen (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.</p><p id="p0051" num="0051">The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, provides information to a cell from which a series of amino acids can be assembled into a specific amino acid sequence to produce an active enzyme. Because of the degeneracy of the genetic code, certain base changes in DNA sequence do not change the amino acid sequence of a protein. It is therefore understood that modifications in a nucleotide sequence encoding any of the proteins of this invention, which do not substantially affect their functional properties, are contemplated.</p><p id="p0052" num="0052">In this description, "expression" denotes the production of the protein product encoded by a gene. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms.</p><heading id="h0008"><b><u>Differentially Expressed Sequences</u></b></heading><p id="p0053" num="0053">The differentially expressed genes referred to in this invention have been identified in several citrus species, exemplified by sweet orange plants. In the context of the present invention, "<i>deg</i>" refers to a <u>d</u>ifferentially expressed <u>g</u>ene whose overexpression confers resistance to plants against plant diseases. Exemplary <i>deg</i> sequences are set forth in "Brief description of the Sequences."<!-- EPO <DP n="8"> --></p><p id="p0054" num="0054">The differentially expressed genes from <i>Citrus sinensis</i> will henceforth be called <i>deg 1</i> (SEQ ID NO: 1), <i>deg 2</i> (SEQ ID NO: 2), <i>deg 3</i> (SEQ ID NO: 3), <i>deg 4</i> (SEQ ID NO: 4), <i>deg 5</i> (SEQ ID NO: 5), <i>deg 6</i> (SEQ ID NO: 6), <i>deg 7</i> (SEQ ID NO: 7), <i>deg 8</i> (SEQ ID NO: 8), <i>deg 9</i> (SEQ ID NO: 9), <i>deg 10</i> (SEQ ID NO: 10), <i>deg 11</i> (SEQ ID NO: 11), <i>deg 12</i> (SEQ ID NO: 12), and <i>deg 13</i> (SEQ ID NO: 13).</p><p id="p0055" num="0055">The terms "sequence identity" and "sequence similarity" can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms. Sequences may then be referred to as "substantially identical" or "essentially similar" when they share at least 70% of sequence identity over their entire length, respectively. Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, Calif. 92121-3752 USA, or EmbossWin version 2.10.0 (using the program "needle"). Alternatively percent similarity or identity may be determined by searching against databases, using algorithm as FASTA, BLAST, etc.</p><p id="p0056" num="0056">As noted above, the present invention provides nucleic acid molecules comprising the nucleotide sequences of SEQ ID NO: 1-13, encoding functional proteins, wherein the proteins have amino acid sequences set forth in SEQ ID NO: 14-26. It is understood that the proteins of the invention encompass amino acid substitutions, additions, and deletions that do not alter the function of any of the proteins.</p><p id="p0057" num="0057">Because many proteins are encoded by gene families, it is expected that other citrus genes could have similar functions as those proteins encoded by SEQ ID NO: 1-13. These genes can be identified and functionally annotated by sequence comparison. A worker skilled in the art can identify a functionally related protein sequence with the aid of conventional methods such as screening cDNA libraries or genomic libraries with suitable hybridization probes. The skilled artisan knows that paralogous sequences can also be isolated with the aid of (degenerate) oligonucleotides and PCR-based methods.</p><p id="p0058" num="0058">Accordingly, the sequences can be identified by the methods described <i>supra,</i> and therefore functionally annotated as belonging to any of the DEG families included in this invention. (Pursuant to common usage, italicization denotes a gene and capitalization an encoded product.) Therefore, the phrase "<i>deg</i> DNA sequence" here refers to any nucleic acid molecule with a nucleotide sequence capable of hybridizing under stringent conditions with any<!-- EPO <DP n="9"> --> of the sequence set forth in SEQ ID NO: 1-13, and coding for a polypeptide equivalent to the proteins having amino acid sequences set forth as SEQ ID NO: 14-26. The term also includes sequences which cross-hybridize with SEQ ID NO: 1-13, preferably having at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with the genes shown in SEQ ID NO: 1-13. The nucleotide sequences of the invention may encode proteins which are homologous to the predicted gene products disclosed herein as SEQ ID NO: 14-26. The invention also includes a protein sequence that preferably is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NO: 14-26.</p><p id="p0059" num="0059">"Stringent conditions" as used herein, refers to parameters with which the art is familiar, such as hybridization in 3.5 x SSC, 1 x Denhardt's solution, 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, and 2m M EDTA for 18 hours at 65°C, followed by 4 washes of the filter at 65°C for 20 minutes, in 2 x SSC, 0.1% SDS, and a final wash for up to 20 minutes in 0.5 x SSC, 0.1% SDS, or 0.3 x SSC and 0.1% SDS for greater stringency, and 0.1 x SSC, 0.1% SDS for even greater stringency. Other conditions may be substituted, as long as the degree of stringency is equal to that provided herein, using a 0.5 x SSC final wash.</p><p id="p0060" num="0060">Accordingly, the present invention comprises any nucleic acid, gene, polynucleotide, DNA, RNA, mRNA, or cDNA molecule from a citrus plant species, or produced synthetically, that increases disease resistance. The DNA or RNA may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also called the anti-sense strand.</p><p id="p0061" num="0061">As used herein, "<i>deg</i> genes as set forth in SEQ ID NO: 1-13" is understood to mean that the <i>deg</i> genes includes the sequences set forth in SEQ ID NO: 1-13, as well as nucleic acid molecules comprised of variants of SEQ ID NO: 1-13, with one or more bases deleted, substituted, inserted, or added, which variant codes for a polypeptide with the same activity. Accordingly, sequences having "base sequences with one or more bases deleted, substituted, inserted, or added" retain physiological activity even when the encoded amino acid sequence has one or more amino acids substituted, deleted, inserted, or added. Due to degeneracy of the genetic code, different nucleotide codons may be used to code for a particular amino acid. A host cell often displays a preferred pattern of codon usage (Campbell et al., 1990). Nucleic acid sequences are preferably constructed to utilize the codon usage pattern of the particular host cell. This generally enhances expression of the nucleic acid sequence in a transformed host cell. The nucleic acid sequences disclosed herein preferably utilize the optimal codon usage for bacterial,<!-- EPO <DP n="10"> --> fungal and plant host cells. _Additionally, multiple forms of the proteins of this invention may exist, which may be due to post-translational modification of a gene product, or to multiple forms of the <i>deg</i> genes. Nucleotide sequences that have such modifications and encode similar proteins are included within the scope of the present invention.</p><p id="p0062" num="0062">For example, the poly A tail or 5'- or 3'-end, nontranslation regions may be deleted, and bases may be deleted to the extent that amino acids are deleted. Bases may also be substituted, as long as no frame shifts result. Bases also may be "added" to the extent that amino acids are added. It is essential; however, that any such modifications do not result in the loss of the protein activity. A modified DNA in this context can be obtained by modifying the DNA base sequences of the invention so that amino acids at specific sites are substituted, deleted, inserted, or added by site-specific mutagenesis, for example. <nplcit id="ncit0017" npl-type="s"><text>Zoller &amp; Smith, Nucleic Acid Res. 10: 6487-500 (1982</text></nplcit>).</p><p id="p0063" num="0063">A <i>deg</i> gene sequence can be synthesized <i>ab initio</i> from the appropriate bases, for example, by using any appropriate protein sequence disclosed herein as a guide to create a DNA molecule that, though different from the native DNA sequence, results in the production of proteins with the same or similar amino acid sequences.</p><p id="p0064" num="0064">By "isolated" nucleic acid molecule(s) means a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a DNA construct are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or DNA molecules that are purified, partially or substantially, in solution. Isolated RNA molecules include in vitro RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules, according to the present invention, further include such molecules produced synthetically.</p><p id="p0065" num="0065">"Exogenous nucleic acid" refers to a nucleic acid, DNA or RNA, which has been introduced into a cell (or the cell's ancestor) through the efforts of humans. Such exogenous nucleic acid may be a copy of a sequence which is naturally found in the cell into which it was introduced, or fragments thereof.</p><p id="p0066" num="0066">In contrast, "endogenous nucleic acid" refers to a nucleic acid, gene, polynucleotide, DNA, RNA, mRNA, or cDNA molecule that is present in the genome of a plant or organism that<!-- EPO <DP n="11"> --> is to be genetically engineered. An endogenous sequence is "native" to, i.e., indigenous to, the plant or organism that is to be genetically engineered.</p><p id="p0067" num="0067">"Heterologous nucleic acid" refers to a nucleic acid, DNA or RNA, which has been introduced into a cell (or the cell's ancestor). Such heterologous nucleic acid may comprise segments that are a copy of a sequence which is naturally found in the cell into which it has been introduced, or fragments thereof.</p><p id="p0068" num="0068">Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer, such as the Model 3730 from Applied Biosystems, Inc. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 95% identical, more typically at least about 96% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence may be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.</p><p id="p0069" num="0069">A "variant" is a nucleotide or amino acid sequence that deviates from the standard, or given, nucleotide or amino acid sequence of a particular gene or protein. The terms "isoform," "isotype," and "analog" also refer to "variant" forms of a nucleotide or an amino acid sequence. An amino acid sequence that is altered by the addition, removal, or substitution of one or more amino acids, or a change in nucleotide sequence may be considered a "variant" sequence. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. A variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted may be found using computer programs well known in the art such as Vector NTI Suite (InforMax, MD) software. "Variant" also may refer to a "shuffled gene," such as those described in Maxygen-assigned patents. For instance, a variant of the present invention may include variants of sequences and desired<!-- EPO <DP n="12"> --> polynucleotides that are modified according to the methods and rationale disclosed in, for example, <patcit id="pcit0002" dnum="US6132970A"><text>U. S. Pat. No. 6,132,970</text></patcit>.</p><heading id="h0009"><b><u>Methods for overexpressing <i>deg</i> genes</u></b></heading><p id="p0070" num="0070">In one aspect of the invention, plant disease resistance is increased by overexpressing a <i>deg</i> gene. Various methods for overexpressing a particular gene are well-known in the art and may be used in the present invention.</p><p id="p0071" num="0071">The present invention contemplates overexpression of a DEG-encoding sequence. Sense polynucleotides employed in carrying out the present invention are of a length sufficient to express a functional protein in a plant cell. Such polynucleotides may be essentially an entire genomic or complementary nucleic acid encoding any the DEG protein included in this invention.</p><p id="p0072" num="0072">The suitability of candidate targets also may be evaluated by testing their accessibility to hybridization with complimentary oligonucleotides, using ribonuclease protection assays as are known in the art. DNA encoding enzymatic RNA molecules may be produced in accordance with known techniques. For example, see <patcit id="pcit0003" dnum="US4987071A"><text>Cech et al., U.S. patent No. 4,987,071</text></patcit>; <patcit id="pcit0004" dnum="US5559021A"><text>Keene et al., U.S. patent No. 5,559,021</text></patcit>; <patcit id="pcit0005" dnum="US5589367A"><text>Donson et al., U.S. patent No. 5,589,367</text></patcit>; <patcit id="pcit0006" dnum="US5583032A"><text>Torrence et al., U.S. patent No. 5,583,032</text></patcit>; <patcit id="pcit0007" dnum="US5580967A"><text>Joyce, U.S. patent No. 5,580,967</text></patcit>; <patcit id="pcit0008" dnum="US5595877A"><text>Gold et al., U.S. patent No. 5,595,877</text></patcit>; <patcit id="pcit0009" dnum="US5591601A"><text>Wagner et al., U.S. patent No. 5,591,601</text></patcit>; and <patcit id="pcit0010" dnum="US5622854A"><text>U.S. patent No. 5,622,854</text></patcit>.</p><p id="p0073" num="0073">For example, <i>deg</i> gene expression may be increased through genetic engineering methods that are well known in the art. Expression can be increased by operably linking a strong promoter sequence to any DEG-encoding sequence included in this invention. Expression may be further increased by adding an enhancer sequence to a strong promoter operably linked to any DEG-encoding sequence included in this invention.</p><p id="p0074" num="0074">"Enhancer" or "enhancer element" refers to a cis-acting transcriptional regulatory element, a.k.a. cis-element, which confers an aspect of the overall expression pattern, but is usually insufficient alone to drive transcription, of an operably linked polynucleotide sequence. Unlike promoters, enhancer elements do not usually include a transcription start site (TSS) or TATA box. A promoter may naturally comprise one or more enhancer elements that affect the transcription of an operably linked polynucleotide sequence. An isolated enhancer element may also be fused to a promoter to produce a chimeric promoter.cis-element, which confers an aspect of the overall modulation of gene expression. A promoter or promoter fragment may comprise<!-- EPO <DP n="13"> --> one or more enhancer elements that effect the transcription of operably linked genes. Many promoter enhancer elements are believed to bind DNA-binding proteins and/or affect DNA topology, producing local conformations that selectively allow or restrict access of RNA polymerase to the DNA template or that facilitate selective opening of the double helix at the site of transcriptional initiation. An enhancer element may function to bind transcription factors that regulate transcription. Some enhancer elements bind more than one transcription factor, and transcription factors may interact with different affinities with more than one enhancer domain. Enhancer elements can be identified by a number of techniques, including deletion analysis, i.e., deleting one or more nucleotides from the 5' end or internal to a promoter; DNA binding protein analysis using DNase I footprinting, methylation interference, electrophoresis mobility-shift assays, in vivo genomic footprinting by ligation-mediated PCR, and other conventional assays; or by DNA sequence similarity analysis using known cis-element motifs or ehnacer elements as a target sequence or target motif with conventional DNA sequence comparison methods, such as BLAST. The fine structure of an enhancer domain can be further studied by mutagenesis (or substitution) of one or more nucleotides or by other conventional methods. Enhancer elements can be obtained by chemical synthesis or by isolation from regulatory elements that include such elements, and they can be synthesized with additional flanking nucleotides that contain useful restriction enzyme sites to facilitate subsequence manipulation. Thus, the design, construction, and use of enhancer elements according to the methods disclosed herein for modulating the expression of operably linked transcribable polynucleotide molecules are encompassed by the present invention. Several enhancers are known in the art including the 35S CaMV enhancers.</p><heading id="h0010"><b><u>Nucleic Acid Constructs</u></b></heading><p id="p0075" num="0075">In accordance with one aspect of the invention, one or more sequences that increase disease resistance are incorporated into a nucleic acid construct that is suitable for plant or cell transformation. The invention provides nucleic acid molecules that increase disease resistance in a transformed plant.</p><p id="p0076" num="0076">Recombinant nucleic acid constructs may be made using standard techniques. For example, a nucleotide sequence for transcription may be obtained by treating a vector containing said sequence with restriction enzymes to cut out the appropriate segment. The nucleotide sequence for transcription may also be generated by annealing and ligating synthetic oligonucleotides or by using synthetic oligonucleotides in a polymerase chain reaction (PCR) to give suitable restriction sites at each end. The nucleotide sequence then is cloned into a vector<!-- EPO <DP n="14"> --> containing suitable regulatory elements, such as upstream promoter and downstream terminator sequences.</p><p id="p0077" num="0077">An important aspect of the present invention is the use of nucleic acid constructs wherein a DEG-encoding sequence is operably linked to one or more regulatory sequences, which drive expression of the sequence in certain cell types, organs, or tissues without unduly affecting normal development or physiology.</p><p id="p0078" num="0078">"Promoter" connotes a region of DNA upstream from the start of transcription that is involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "constitutive promoter" is one that is active throughout the life of the plant and under most environmental conditions. Tissue-specific, tissue-preferred, cell type-specific, and inducible promoters constitute the class of "non-constitutive promoters." "Operably linked" refers to a functional linkage between a promoter and a second sequence, where the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. In general, "operably linked" means that the nucleic acid sequences being linked are contiguous.</p><p id="p0079" num="0079">Suitable promoters are illustrated by but are not limited to constitutive promoters such as the cauliflower mosaic virus (CaMV) 35S promoter or the polyubiquitin promoter, as well as tissue-specific, tissue-preferred, cell type-specific, and inducible promoters. For example, in citrus, several important pathogens are located in the vascular system, which refers to either the xylem or the phloem vessels; it may be advantageous to use a xylem/phloem-specific promoter to target the expression of a defense gene. Xylem or Phloem specific promoters are known in the art, for example, those disclosed in <patcit id="pcit0011" dnum="US6613960B"><text>U.S. Patent No. 6,613,960</text></patcit> and <patcit id="pcit0012" dnum="US20040253717A"><text>U.S. Application Publication Nos. 2004/0253717 </text></patcit>and <patcit id="pcit0013" dnum="US20070266457A"><text>2007/0266457</text></patcit>.</p><p id="p0080" num="0080">The vectors of the invention may also contain termination sequences, which are positioned downstream of the nucleic acid molecules of the invention, such that transcription of mRNA is terminated, and polyA sequences added. Exemplary of such terminators are the cauliflower mosaic virus (CaMV) 35S terminator and the nopaline synthase gene (Tnos) terminator. The expression vector also may contain enhancers, introns, start codons, splicing signal sequences, and targeting sequences to cellular organelles such as mitochondria and chlroplasts.<!-- EPO <DP n="15"> --></p><p id="p0081" num="0081">Expression vectors of the invention may also contain a selection marker by which transformed cells can be identified in culture. The marker may be associated with the heterologous nucleic acid molecule, i.e., the gene operably linked to a promoter. As used herein, the term "marker" refers to a gene encoding a trait or a phenotype that permits the selection of, or the screening for, a plant or cell containing the marker. In plants, for example, the marker gene will encode antibiotic or herbicide resistance. This allows for selection of transformed cells from among cells that are not transformed or transfected.</p><p id="p0082" num="0082">Examples of suitable selectable markers include adenosine deaminase, dihydrofolate reductase, hygromycin-B-phosphotransferase, thymidne kinase, xanthine-guanine phospho-ribosyltransferase, glyphosate and glufosinate resistance, and amino-glycoside 3'-O-phosphotranserase (kanamycin, neomycin and G418 resistance). These markers may include resistance to G418, hygromycin, bleomycin, kanamycin, spectinomycin, and gentamicin. The construct may also contain the selectable marker gene <i>ahas</i> that confers resistance to herbicides such as imazethapyr, imazapic, imazapyr, imazamox, sulfometuron methyl, imazaquin, chlorimuron ethyl, metsulfuron methyl, rimsulfuron, thifensulfuron methyl, pyrithiobac sodium, tribenuron methyl, and nicosulfuron [<i>sic</i>: "imidazolinone class"]. <nplcit id="ncit0018" npl-type="s"><text>Sun-Mi et al., 2004, Biochemical Journal 383: 53-61</text></nplcit>. Other suitable selection markers are known as well.</p><p id="p0083" num="0083">Visible markers such as green florescent protein (GFP) may be used. Methods for identifying or selecting transformed plants based on the control of cell division have also been described. See <patcit id="pcit0014" dnum="WO2000052168A"><text>WO 2000/052168</text></patcit> and <patcit id="pcit0015" dnum="WO2001059086A"><text>WO 2001/059086</text></patcit>.</p><p id="p0084" num="0084">Replication sequences, of bacterial or viral origin, may also be included to allow the vector to be cloned in a bacterial or phage host. Preferably, a broad host range prokaryotic origin of replication is used. A selectable marker for bacteria may be included to allow selection of bacterial cells bearing the desired construct. Suitable prokaryotic selectable markers also include resistance to antibiotics such as kanamycin or tetracycline.</p><p id="p0085" num="0085">Other nucleic acid sequences encoding additional functions may also be present in the vector, as is known in the art. For instance, when <i>Agrobacterium</i> is the host, T-DNA sequences may be included to facilitate the subsequent transfer to and incorporation into plant chromosomes.<!-- EPO <DP n="16"> --></p><heading id="h0011"><b><u>Plants for Genetic Engineering</u></b></heading><p id="p0086" num="0086">The present invention comprehends the genetic manipulation of plants, especially citrus, to enhance disease resistance.</p><p id="p0087" num="0087">In this description, "plant" denotes any cellulose-containing plant material that can be genetically manipulated, including but not limited to differentiated or undifferentiated plant cells, protoplasts, whole plants, plant tissues, or plant organs, or any component of a plant such as a leaf, stem, root, bud, tuber, fruit, rhizome, or the like. As used herein, "propagule" includes a structure with the capacity to give rise to a new plant, e.g., a seed, a spore, or a part of the vegetative body capable of independent growth if detached from the parent.</p><p id="p0088" num="0088">Plants that can be engineered in accordance with the invention include but are not limited to trees, such as sweet oranges, lemons, tangerines,etc. "Citrus plant" is understood as meaning a plant of the genera <i>Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia,</i> and <i>Eremocitrus,</i> preferably the species <i>Citrus sinensis.</i></p><p id="p0089" num="0089">In the present description, "transgenic plant" refers to a plant that has incorporated a DNA sequence, including but not limited to genes that are not normally present in a host plant genome, DNA sequences not normally transcribed into RNA or translated into a protein ("expressed"), or any other genes or DNA sequences that one desires to introduce into the non-transformed plant, such as genes that normally may be present in the non-transformed plant but that one desires either to genetically engineer or to have altered expression. The "transgenic plant" category includes both a primary transformant and a plant that includes a transformant in its lineage, e.g., by way of standard introgression or another breeding procedure.</p><p id="p0090" num="0090">"Genetically engineered" (GE) encompasses any methodology for introducing a nucleic acid or specific mutation into a host organism. For example, a citrus plant is genetically engineered when it is transformed with a polynucleotide sequence that increases the expression of a gene, such as any <i>deg</i> gene, and thereby increases disease resistance. In contrast, a citrus plant that is not transformed with a polynucleotide sequence is a control plant and is referred to as a "non-transformed" plant.</p><heading id="h0012"><b><u>Methods for Genetic Engineering</u></b></heading><p id="p0091" num="0091">A polynucleotide sequence, such as a <i>deg</i> sequence, may be stably integrated into a plant genome in various ways known to the art. Monocotyledonous, dicotyledonous angiosperm or<!-- EPO <DP n="17"> --> gymnosperm plant cells may be transformed For example, see <nplcit id="ncit0019" npl-type="s"><text>Klein et al., Biotechnology 4: 583-590 (1993</text></nplcit>); <nplcit id="ncit0020" npl-type="s"><text>Bechtold et al., C. R. Acad. Sci. Paris 316:1194-1199 (1993</text></nplcit>); <nplcit id="ncit0021" npl-type="s"><text>Bent et al., Mol. Gen. Genet. 204:383-396 (1986</text></nplcit>); <nplcit id="ncit0022" npl-type="s"><text>Paszowski et al., EMBO J. 3: 2717-2722 (1984</text></nplcit>); <nplcit id="ncit0023" npl-type="s"><text>Sagi et al., Plant Cell Rep. 13: 26 15-286 (1994</text></nplcit>). <i>Agrobacterium</i> species such as <i>A. tumefaciens</i> and <i>A</i>. <i>rhizogenes</i> can be used, for example, in accordance with <nplcit id="ncit0024" npl-type="s"><text>Nagel et al., Microbiol Lett 67: 325 (1990</text></nplcit>). Additionally, plants may be transformed by <i>Rhizobium, Sinorhizobium</i> or <i>Mesorhizobium</i> transformation. <nplcit id="ncit0025" npl-type="s"><text>Broothaerts et al., Nature 433:629-633 (2005</text></nplcit>). <i>See</i> <patcit id="pcit0016" dnum="US200702711627A"><text>U.S. Application Publication 200702711627</text></patcit>.</p><p id="p0092" num="0092">Additional methods for genetically engineering a plant or cell include, but are not limited to, electroporation, particle gun bombardment (<nplcit id="ncit0026" npl-type="s"><text>Klein et al. (1987) Nature. 327:70-73</text></nplcit>), calcium phosphate precipitation, and polyethylene glycol fusion, transfer into germinating pollen grains, direct transformation (<nplcit id="ncit0027" npl-type="s"><text>Lorz et al., Mol. Genet. 199: 179-182 (1985</text></nplcit>)), and other methods known to the art. If a selection marker, such as kanamycin resistance, is employed, it makes it easier to determine which cells have been successfully transformed. Marker genes may be included within pairs of recombination sites recognized by specific recombinases such as cre or flp to facilitate removal of the marker after selection. See <patcit id="pcit0017" dnum="US20040143874A"><text>U. S. published application No. 2004/0143874</text></patcit>.</p><p id="p0093" num="0093">In the context of the present invention the transgenic plants produced by the method described supra can be used as a source of a transgene in a conventional breeding program. In general, pollen from a transgenic plant is used to pollinate a non-transgenic plant. The seeds of the mother plant can be used to produce a new transgenic plant different from the original transgenic plant produced by the method described supra.</p><p id="p0094" num="0094">Genetically engineered plants are selected that have increased expression of <i>deg</i> genes. For example, a transgenic citrus plant/plant cells employed in the method according to the invention are distinguished from citrus wild- type plants/plant cells by the fact that they comprise at least one copy of the nucleic acid molecule set for in SEQ ID NO: 1-13 stably integrated into their genome in addition to copies of such a molecule which occur naturally in the citrus wild-type plants/plant cells. In this case, the citrus plants/plant cells of the method according to the invention can be distinguished from citrus wild-type plants/plant cells in particular by the fact that this additional copy, or these additional copies, is/are located at locations in the genome where it does not occur, or where they do not occur, in citrus wild-type plants/plant cells.<!-- EPO <DP n="18"> --></p><p id="p0095" num="0095">"Citrus wild- type plant" refers to control plants whose genome is not modified by the introduction of a construct comprising any <i>deg</i> gene sequence, or fragment thereof.</p><heading id="h0013"><b><u>Methods for Quantifying Increased Disease Resistance</u></b></heading><p id="p0096" num="0096">Genetically engineered plants and cells of the invention are characterized by an enhanced disease resistance. This is achieved by overexpressing <i>deg</i> genes.</p><p id="p0097" num="0097">"Disease resistance" or "increased/enhanced disease resistance" refers to an enhanced ability of transformants (compared to wild type or control transformants) to withstand the attack of one or more plant pathogens, or in other words, it refers to a significant reduction in disease symptoms in transformants compared to non-transformed (or empty-vector transformed) controls. Disease resistance or enhanced disease resistance may be determined using a variety of methods. Often disease symptoms are scored visually (either in bioassays or in the field) by assessing the disease symptoms at one or more time points after inoculation or contact with a pathogen. Alternative methods include methods whereby the pathogen is detected and optionally quantified. A transgenic plant may thus show enhanced disease resistance if the amount of pathogen detected in/on the tissue is significantly less compared to controls, or if the pathogen spread is significantly slower than in controls. Ultimately, a significant increase in average yield of transformants (e.g. at least 1%, 2%, 5%, 10% or more) compared to controls, when grown under equivalent disease pressure (preferably in the field) provides an indirect measurement of enhanced disease resistance.</p><p id="p0098" num="0098">Thus, a plurality of transformed plants expressing DEG proteins (or a constitutively active DEG protein) show enhanced disease resistance if they show a significant reduction of disease symptoms, compared to the untransformed or empty-vector transformed controls. Statistical analysis is required to determine whether significant differences exist. Preferably, one or more disease symptoms are on average at least 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, or even 100% lower in DEG transformants than in the control plants. As the disease assay is different for every host-pathogen combination, no specific protocol can be provided, but the skilled person knows how to determine whether transformants show significantly enhanced disease resistance to one or more pathogens. Bioassays as known in the art for each plant-pathogen combination can be used to compare resistance of transgenic plants to suitable controls.</p><p id="p0099" num="0099">Detailed descriptions of plant pathogens, the disease symptoms caused by them and their life cycles can be found for each plant species. For example, citrus pathogens are described in<!-- EPO <DP n="19"> --> <nplcit id="ncit0028" npl-type="b"><text>COMPENDIUM OF CITRUS DISEASES, Editors L. W. Timmer, Stephen Michael Garnsey, and J. H. Graham (ISBN 0-89054-248-1, APS Press</text></nplcit>).</p><p id="p0100" num="0100">Pathogens of citrus include, for example, the following fungal and bacterial species and viruses (non-limiting): <i>Xanthomonas campestris</i> pv. <i>citrumelo</i> (Bacterium), <i>Pseudomonas syringae</i> (Bacterium), <i>Xanthomonas axonopodis</i> pv. <i>citri</i> (Bacterium), <i>Xylella fastidiosa</i> (Bacterium), <i>Candidatus</i> Liberibacter africanus (Bacterium), <i>Candidatus</i> Liberibacter americanus (Bacterium), <i>Candidatus</i> Liberibacter asiaticus (Bacterium), <i>Alternaria alternata</i> (Fungus), <i>Aspergillus flavus, Alternaria alternata</i> (Fungus), <i>Alternaria citri</i> (Fungus), <i>Glomerella cingulata</i> (Fungus), <i>Colletotrichum gloeosporioides</i> (Fungus), <i>Thanatephorus cucumeris</i> (Fungus), <i>Rhizoctonia solani</i> (Fungus), <i>Aspergillus niger</i> (Fungus), <i>Thielaviopsis basicola</i> (Fungus), <i>Chalara elegans</i> (Fungus), <i>Guignardia citricarpa</i> (Fungus), <i>Phyllosticta citricarpa</i> (Fungus), <i>Penicillium italicum</i> (Fungus), <i>Botrytis cinerea</i> (Fungus), <i>Botryotinia fuckeliana</i> (Fungus), <i>Sphaeropsis tumefaciens</i> (Fungus), <i>Phytophthora citricola, P. citrophthora, P. hibernalis, P. nicotianae, P. parasitica, P. palmivora, P. syringae, Macrophomina phaseolina</i> (Fungus), <i>Pythium sp., P. aphanidermatum, P. debaryanum, P. rostratum, P. ultimum, P. vexans, Rhizoctonia solani</i> (Fungus), <i>Lasiodiplodia theobromae</i> (Fungus), <i>Botryodiplodia theobromae</i> (Fungus), <i>Diplodia natalensis</i> (Fungus), <i>Botryosphaeria rhodina</i> (Fungus), <i>Botryosphaeria ribis</i> (Fungus), <i>Nectria haematococca</i> (Fungus), <i>Schizothyrium pomi</i> (Fungus), <i>Fusarium oxysporum</i> (Fungus), <i>Botrytis cinerea</i> (Fungus), <i>Mycosphaerella citri</i> (Fungus), <i>Penicillium digitatum</i> (Fungus), <i>Ganoderma applanatum</i> (Fungus), <i>G. brownii</i> (Fungus), <i>G. lucidum</i> (Fungus), <i>Mycosphaerella horii</i> (Fungus), <i>M. lageniformis</i> (Fungus), <i>Phoma tracheiphila</i> (Fungus), <i>Alternaria limicola</i> (Fungus), <i>Diaporthe citri</i> (Fungus), <i>Phomopsis citri</i>(Fungus), <i>Mucor paronychia</i> (Fungus), <i>M. racemosus</i> (Fungus), <i>Armillaria mellea</i> (Fungus), <i>Phaeoramularia angolensis</i> (Fungus), <i>Phymatotrichopsis omnivora</i> (Fungus), <i>Phomopsis citri</i> (Fungus), <i>Erythricium salmonicolor</i> (Fungus), <i>Gliocladium roseum</i> (Fungus), <i>Pleospora herbarum</i> (Fungus), <i>Oxyporus latemarginatus</i> (Fungus), <i>Poria latemarginata</i> (Fungus), <i>Colletotrichum acutatum</i> (Fungus), <i>Oidium tingitaninum</i> (Fungus), <i>Acrosporium tingitaninum</i> (Fungus), <i>Rhizopus stolonifer</i> (Fungus), <i>Lasiodiplodia theobromae</i> (Fungus), <i>Hendersonula toruloidea</i> (Fungus), <i>Elsinoë fawcettii</i> (Fungus), <i>Sclerotinia sclerotiorum</i> (Fungus), <i>Septoria citri</i> (Fungus), <i>Gloeodes pomigena</i> (Fungus), <i>Geotrichum citri-aurantii</i> (Fungus), <i>Galactomyces citri-aurantii</i>(Fungus), <i>G. candidum</i> (Fungus), <i>Galactomyces geotrichum</i> (Fungus), <i>Elsinoë australis</i> (Fungus), <i>Corticium stevensii</i> (Fungus), <i>Pellicularia koleroga</i> (Fungus), <i>Trichoderma viride</i><!-- EPO <DP n="20"> --> (Fungus), <i>Rhytidhysteron rufulum</i> (Fungus), <i>Ustulina deusta</i> (Fungus), <i>Penicillium ulaiense</i> (Fungus), <i>Rosellinia necatrix</i> (Fungus), <i>R. subiculata</i> (Fungus), <i>Citrus mosaic virus, Satsuma dwarf-related virus, Citrus leaf rugose virus, Citrus yellow mosaic virus, Crinkly leaf virus, Citrus variegation virus</i> (CVV), <i>Satsuma dwarf virus</i> (SDV), <i>Citrus tatter leaf virus, Citrus tristeza virus</i> (CTV), <i>Citrus sudden death virus</i> (CSDV), <i>Citrus cachexia viroid, Citrus yellow mottle viroid, Citrus yellow ringspot viroid, Citrus exocortis viroid</i> (CEVd), <i>Citru Leprosis virus</i> (CiLV). Due to the non-specific plant defense, it could be expected that genes are effective against other bacteria pathogens.</p><p id="p0101" num="0101">It is also an embodiment to generate transgenic plants which express several DEG proteins, preferably under the control of different promoters, such as different tissue-specific promoters.</p><p id="p0102" num="0102">The disease resistance phenotype can be fine-tuned by expressing a suitable amount of DEG proteins at a suitable time and location. Such fine-tuning may be done by determining the most appropriate promoter for a particular host-pathogen combination and also by selecting transgenic "events" which show the desired expression level. A too low level of DEG proteins or too slow induction of DEG protein production following pathogen attack may be insufficient to enhance disease resistance levels. On the other hand, a too high protein level or expression at times and locations devoid of pathogen attack, may result in agronomically undesired phenotypes, such as lesions in leaves or fruit in the absence of pathogens and yield penalties. However, the skilled person can easily generate plants having enhanced disease resistance, but which at the same time are agronomical acceptable. Optimal <i>deg</i> alleles may be isolated or identified as described, e.g., alleles providing high resistance levels and only a weak HR phenotype.</p><p id="p0103" num="0103">Transformants expressing desired levels of DEG proteins are selected by e.g. analysing copy number (Southern blot analysis), mRNA transcript levels (e.g. RT-PCR using specific <i>deg</i> primer pairs or flanking primers) or by analysing the presence and level of DEG proteins in various tissues (e.g. SDS-PAGE; ELISA assays, etc). For regulatory reasons, preferably single copy transformants are preferably selected and the sequences flanking the site of insertion of the chimeric gene is analysed, preferably sequenced to characterize the "event." High or moderate DEG-expressing transgenic events are selected for further testing until a high performing elite event with a stable <i>deg</i> transgene is obtained.<!-- EPO <DP n="21"> --></p><p id="p0104" num="0104">Transformants expressing one or more <i>deg</i> genes according to the invention may also comprise other transgenes, such as other genes conferring disease resistance or conferring tolerance to other biotic and/or abiotic stresses. To obtain such plants with "stacked" transgenes, other transgenes may either be introgressed into the DEG transformants, or the DEG transformants may be transformed subsequently with one or more other genes, or alternatively several chimeric genes may be used to transform a plant line or variety. For example, several chimeric genes may be present on a single vector, or may be present on different vectors which are co-transformed. Single events containing one or more <i>deg</i> genes can be bred with other events containing one ore more of other <i>deg</i> genes to obtain a stacked event with several <i>deg</i> genes.</p><p id="p0105" num="0105">In one embodiment the following genes are combined with one or more <i>deg</i> genes according to the invention: known disease resistance genes, especially genes conferring enhanced resistance to necrotophic pathogens, virus resistance genes, insect resistance genes, abiotic stress resistance genes (e.g. drought tolerance, salt tolerance, heat- or cold tolerance, etc.), herbicide resistance genes, and the like. The stacked transformants may thus have an even broader biotic and/or abiotic stress tolerance, to pathogen resistance, insect resistance, nematode resistance, salinity, cold stress, heat stress, water stress, etc. Also, <i>deg</i> silencing approaches may be combined with <i>deg</i> expression approaches in a single plant. For example, <i>deg</i> overexpression in rootstocks or scions may confer or enhance rootstock or scion resistance to soil pathogens, vascular pathogens or leaf pathogens.</p><p id="p0106" num="0106">It is also possible to introduce or introgress <i>deg</i> genes into a plant breeding line which already has a certain level of disease resistance. For durability of disease resistance in the field, it may be desirable to stack several disease resistance mechanisms in a plant, preferably whereby the resistance sources have different underlying molecular mechanisms.</p><p id="p0107" num="0107">Whole plants, seeds, cells, tissues and progeny (such as F1 hybrids, F2 seeds/plants, etc.) of any of the transformed plants described above are encompassed herein and can be identified by the presence of the transgene in the DNA, for example by PCR analysis using total genomic DNA as template and using <i>deg</i> specific PCR primer pairs. Also "event specific" PCR diagnostic methods can be developed, where the PCR primers are based on the plant DNA flanking the inserted chimeric gene, see <patcit id="pcit0018" dnum="US6563026B"><text>U.S. Pat. No. 6,563,026</text></patcit>. Similarly, event specific AFLP fingerprints or RFLP fingerprints may be developed which identify the transgenic plant or any plant, seed, tissue or cells derived there from.<!-- EPO <DP n="22"> --></p><p id="p0108" num="0108">It is understood that the transgenic plants according to the invention preferably do not show non-desired phenotypes, such as yield reduction, enhanced susceptibility to diseases (especially to necrotrophs) or undesired architectural changes (dwarfing, deformations) etc. and that, if such phenotypes are seen in the primary transformants, these can be removed by normal breeding and selection methods (crossing/backcrossing/selfing, etc.). Any of the transgenic plants described herein may be homozygous or hemizygous for the transgene.</p><p id="p0109" num="0109">Specific examples are presented below of methods for obtaining <i>deg</i> genes as well as methods for introducing the target gene into citrus to produce plant transformants. They are meant to be exemplary and not as limitations of the present invention.</p><heading id="h0014"><b>EXAMPLE 1.</b></heading><heading id="h0015"><b>Identification of citrus <i>deg</i> genes</b></heading><p id="p0110" num="0110">Sweet orange plants were inoculated by infiltration with a bacterial suspension of 10<sup>8</sup> CFU/mL of <i>Xanthomonas axonopodis</i> pv citri, causal agent of citrus canker disease. In a parallel experiment, leaves of the same variety were inoculated with a bacterial suspension of 10<sup>8</sup> CFU/mL of <i>Xanthomonas axonopodis</i> pv aurantifolii known to elicit a HR in sweet orange plants. A total of four cDNA libraries were constructed from leaf tissue at 0, 12, 24 and 48 hours after the exposure to those bacterial strains. A total of 3000 sequences were produced for each library and clusters were assembled using the CAP3 software (<nplcit id="ncit0029" npl-type="s"><text>Huang, X. and Madan, A. (1999) CAP3: A DNA sequence assembly program. Genome Res., 9, 868-877</text></nplcit>). The putative identity of each cluster sequence was determined by comparison with public databases using the BLAST algorithm (<nplcit id="ncit0030" npl-type="s"><text>Altschul et al., 1997, Nucleic Acid Res. 25:3389-3402</text></nplcit>).</p><p id="p0111" num="0111">Differential expression was determined by calculating the relative abundance of ESTs of a particular cluster in each of the constructed libraries (<nplcit id="ncit0031" npl-type="s"><text>Steckel and Falciani, 2000, Genome Research 10:2055-2061</text></nplcit>). The probability that this differential expression was not caused by a random event was confirmed by statistical tests (<nplcit id="ncit0032" npl-type="s"><text>Steckel and Falciani, 2000, Genome Research 10:2055-2061</text></nplcit>).</p><p id="p0112" num="0112">Comparison of the expression profiles of a large number of genes identified in this study indicated that, under disease resistance conditions (HR), several genes exhibited significantly higher levels of expression as compared to diseased tissue (<figref idrefs="f0001">Figure 1</figref>). Among them, a total of 13<!-- EPO <DP n="23"> --> genes (SEQ ID NO: 1-13) were chosen as potential candidates to confer disease resistance in citrus plants (<figref idrefs="f0002">Figure 2</figref>).</p><heading id="h0016"><b>EXAMPLE 2</b></heading><heading id="h0017"><b>Vector construction</b></heading><p id="p0113" num="0113">The ORF (<u>o</u>pen <u>r</u>eading <u>f</u>rame) of each candidate gene (SEQ ID NO: 1-13) was PCR amplified using specific primers for the 5' end and 3' end of each gene. Each primer sequence was modified to include the specific sequences required by the GATEWAY<sup>™</sup> cloning system (Invitrogen). The amplification products were first cloned into the vector pENTR/TEV/D-TOPO® (Invitrogen) by recombination and their sequence was confirmed by re-sequencing the whole insert. After confirmation of the sequence, the candidate genes were transferred to plasmid pAH35GW by recombination resulting in the generic construct pr35S(2x)-CaMV::ahas::35SpolyA | pr35S-CaMV::<i>deg</i>::NOSpolyA (<figref idrefs="f0003">Figure 3</figref>). The sequence of the resulting constructs was confirmed by re-sequencing the entire TDNA region. Fully validated vectors were used for citrus transformation.</p><heading id="h0018"><b>EXAMPLE 3</b></heading><heading id="h0019"><b>Citrus transformation</b></heading><p id="p0114" num="0114">Seeds of sweet orange plants cv. Pineapple were germinated in the absence of light for 30 days. Epicotyls of etiolated seedling were cut and infected with <i>Agrobacterium tumefasciens</i> carrying each of the candidate genes (SEQ ID NO: 1-13) in a construct. Approximately 40 days after transformation, regenerated plants were individualized and top-grafted onto rootstock seedlings. Grafted plants remained under laboratory conditions for about 2 months when they were transferred to greenhouse conditions. Before initiating the acclimation period, plants were grafted again onto well-developed rootstock plants grown under greenhouse conditions. Acclimation and development of the scion was allowed to last 70 days after which period they were transferred to mother plant blocks.<!-- EPO <DP n="24"> --></p><heading id="h0020"><b>EXAMPLE 4</b></heading><heading id="h0021"><b>Enhanced disease resistance in citrus plants carrying the pr35S-CaMV::<i>deg</i>::NOSpolyA constructs</b></heading><p id="p0115" num="0115">To assess the effect of increasing expression of <i>deg</i> genes in transgenic citrus plants, a total of 5 leaves were detached from each of 25 independent transgenic events for each of the constructs transformed into citrus plants and 3 non-transgenic wild type plants of the sweet orange variety "Pineapple." In summary, each leaf was perforated 6 times using a needle and each hole was immediately put in contact with 5 µl of a bacterial suspension of 10<sup>6</sup> CFU/ml. Inoculated leaves were incubated in individual humidity chambers and evaluated daily for 15 days. Canker lesions were scored using a proprietary diagrammatic scale (<figref idrefs="f0004">Figure 4</figref>). Analysis of variance (ANOVA) and Dunnett's test for mean comparison for all measurements were performed with the R software package version 2.6.2.</p><p id="p0116" num="0116">During the course of the experiments, several pr35S-CaMV::<i>deg</i>::NOSpolyA events exhibited a reduced canker development as compared to control leaves. After 15 days incubation, the results indicated that some of the transgenic events exhibited a significant reduction on the severity of the canker symptoms as compared to control plants (<figref idrefs="f0005">Figure 5</figref>). All together, overexpression of <i>deg</i> genes appear to cause, at various degrees, changes in the plant defense system that lead to increased disease resistance.</p><heading id="h0022"><b>EXAMPLE 5</b></heading><heading id="h0023"><b>Differential growth rate of the citrus canker bacterium in citrus plants carrying the pr35S-CaMV::<i>deg</i>::NOSpolyA constructs</b></heading><p id="p0117" num="0117">In order to determine the direct effect of the expression of <i>deg</i> genes in transgenic citrus plants on the growth of pathogenic bacterial populations, a total of 3 leaves were detached from the best transgenic events identified by the <i>in vitro</i> assay described before and from 3 non-transgenic wild type plants of the sweet orange variety "Pineapple." In summary, each leaf was perforated 6 times using a needle and each hole was immediately put in contact with 5 µl of a bacterial suspension of 10<sup>5</sup> CFU/ml. Inoculated leaves were incubated in individual humidity chambers and evaluated 0 and 5 days after inoculation. For each evaluation, 3 leaf discs of about 1 cm<sup>2</sup> were cut directly from 3 inoculation sites. Each individual discs was ground in liquid<!-- EPO <DP n="25"> --> nitrogen and used for total DNA extraction using the Wizard<sup>®</sup> Genomic DNA Purification Kit (Promega). DNA from each individual extraction was used for bacterial enumeration using qPCR (<nplcit id="ncit0033" npl-type="s"><text>Cubero &amp; Graham, 2005, Phytopathology 95: 1333-1340</text></nplcit>). Bacterial growth rate was calculated by comparing bacterial populations at 0 and 5 days after de inoculation. Analysis of variance (ANOVA) and Dunnett's test for mean comparison for all measurements were performed with the R software package version 2.6.2.</p><p id="p0118" num="0118">The results indicated a significant reduction in the growth rate of the citrus canker bacterium when <i>deg</i> genes were overexpressed in citrus tissue (<figref idrefs="f0006">Figure 6</figref>). These results also confirmed the observations made for the same events regarding the significant reduction of the severity of the disease (<figref idrefs="f0005">Figures 5</figref> and <figref idrefs="f0006">6</figref>).</p><heading id="h0024"><b>EXAMPLE 6</b></heading><heading id="h0025"><b>Transgene expression levels in selected events carrying the pr35S-CaMV::<i>deg</i>::NOSpolyA constructs</b></heading><p id="p0119" num="0119">In order to examine the correlation between the level of expression of transgenes and the response of different events to the citrus canker pathogen, a group of transgenic events was selected for the quantification of transcript levels using qRT-PCR. In summary, total RNA was extracted from young citrus leaves using the SV Total RNA Isolation System (Promega, Madison, WI) according to the manufacturer's instructions. First-strand cDNA was generated by reverse transcription of 1 µg total RNA per sample with Oligo-dT primer using the ImProm-II™ Reverse Transcriptase System (Promega) according to the manufacturer's instructions in a final reaction volume of 20 µL. For RT-PCR, 5 µL of cDNA was added to 12.5 µL of SYBR® Green Master Mix (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions to achieve a final reaction volume of 25 µL. RT-PCR was performed using an ABI PRISM® 7000 System (Applied Biosystems). The PCR protocol consisted of: initiation at 1 cycle at 50°C for 2 min and 1 cycle at 95°C for 10 min, followed by amplification for 45 cycles at 95°C for 15 sec and 60°C for 1 min. Ct data were collected via ABI PRISM® 7000 Sequence Detection System (Applied Biosystems). Each leaf sample was assayed for each gene a minimum of two separate times.</p><p id="p0120" num="0120">The results indicated a significant variation in the expression level of the transgenes among selected events. However, a significant correlation was observed between the expression<!-- EPO <DP n="26"> --> level of a given transgene (<figref idrefs="f0007">Figure 7</figref>) and the ability of the corresponding event to limit the growth rate of the bacterium (<figref idrefs="f0006">Figure 6</figref>) which, consequently, reduced the severity of the canker lesions (<figref idrefs="f0005">Figure 5</figref>).<br/>
An isolated nucleic acid sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 14-26.<br/>
A construct comprising a nucleotide sequence set forth in SEQ ID NO: 1-13.<br/>
The construct as defined above, wherein said nucleotide sequence is operatively linked to a promoter which functions in plants and said promoter expresses a polypeptide sequence set forth in SEQ ID NO: 14-26.<br/>
The construct as defined above, wherein the promoter is selected from the group consisting of a CaMV 35S promoter, polyubiquitin promoter, tissue specific promoter, and a tissue preferred promoter.<br/>
A plant cell comprising the construct as defined above.<br/>
A method for increasing resistance to citrus canker disease in a plant or cell, comprising overexpressing at least one nucleotide sequence set forth in SEQ ID NO: 1-13.<br/>
A method for increasing resistance to citrus canker disease in a plant or cell, comprising
<ol><li>(a) transforming a plant or cell with a construct comprising at least one nucleotide sequence set forth in SEQ ID NO: 1-13, operably linked to a promoter active in plant cells;</li><li>(b) regenerating a plant from said transformed plant or cell;</li><li>(c) selecting a plant or cell that has increased resistance to citrus canker disease relative to a control plant.</li></ol>
The method as defined above, wherein the promoter is a constitutive promoter or a tissues specific promoter.<br/>
The method as defined above, wherein the tissue specific promoter is a xylem-specific promoter, phloem-specific promoter, or a xylem/phloem-specific promoter.<br/>
The method as defined above,, wherein the promoter is operably linked to an enhancer.<br/>
The method as defined above, wherein the plant is a member of the Rutaceae family.<br/>
The method as defined above,, wherein said plant is selected from the genera of <i>Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia,</i> and <i>Eremocitrus.</i><br/>
A plant, plant cell, seed, or fruit produced by the method as defined above.<br/>
A transgenic plant having incorporated into its genome a nucleotide sequence that encodes a disease resistance polypeptide set forth in SEQ ID NO: 14-26.<br/>
<!-- EPO <DP n="27"> -->The transgenic plant as defined above, wherein the polypeptide is encoded by a nucleotide sequence set forth in SEQ ID NO: 1-13.<br/>
A progeny, fruit, or seed of the plant as defined above, comprising said nucleotide sequence.<!-- EPO <DP n="28"> -->
<img id="ib0001" file="imgb0001.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="29"> -->
<img id="ib0002" file="imgb0002.tif" wi="157" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="30"> -->
<img id="ib0003" file="imgb0003.tif" wi="155" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="31"> -->
<img id="ib0004" file="imgb0004.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="32"> -->
<img id="ib0005" file="imgb0005.tif" wi="157" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="33"> -->
<img id="ib0006" file="imgb0006.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="34"> -->
<img id="ib0007" file="imgb0007.tif" wi="157" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="35"> -->
<img id="ib0008" file="imgb0008.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="36"> -->
<img id="ib0009" file="imgb0009.tif" wi="136" he="232" img-content="dna" img-format="tif"/><!-- EPO <DP n="37"> -->
<img id="ib0010" file="imgb0010.tif" wi="135" he="232" img-content="dna" img-format="tif"/><!-- EPO <DP n="38"> -->
<img id="ib0011" file="imgb0011.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="39"> -->
<img id="ib0012" file="imgb0012.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="40"> -->
<img id="ib0013" file="imgb0013.tif" wi="135" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="41"> -->
<img id="ib0014" file="imgb0014.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="42"> -->
<img id="ib0015" file="imgb0015.tif" wi="135" he="230" img-content="dna" img-format="tif"/><!-- EPO <DP n="43"> -->
<img id="ib0016" file="imgb0016.tif" wi="135" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="44"> -->
<img id="ib0017" file="imgb0017.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="45"> -->
<img id="ib0018" file="imgb0018.tif" wi="130" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="46"> -->
<img id="ib0019" file="imgb0019.tif" wi="136" he="232" img-content="dna" img-format="tif"/><!-- EPO <DP n="47"> -->
<img id="ib0020" file="imgb0020.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="48"> -->
<img id="ib0021" file="imgb0021.tif" wi="135" he="232" img-content="dna" img-format="tif"/><!-- EPO <DP n="49"> -->
<img id="ib0022" file="imgb0022.tif" wi="135" he="232" img-content="dna" img-format="tif"/><!-- EPO <DP n="50"> -->
<img id="ib0023" file="imgb0023.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="51"> -->
<img id="ib0024" file="imgb0024.tif" wi="158" he="148" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56983179" lang="EN" load-source="patent-office"><!-- EPO <DP n="52"> --><claim id="c-en-0001" num="0001"><claim-text>An isolated nucleic acid sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 15-26.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>A construct comprising a nucleotide sequence set forth in SEQ ID NO: 2-13.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The construct of claim 2, wherein said nucleotide sequence is operatively linked to a promoter which functions in plants and said promoter expresses a polypeptide sequence set forth in SEQ ID NO: 15-26.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The construct of claim 3, wherein the promoter is selected from the group consisting of a CaMV 35S promoter, polyubiquitin promoter, tissue specific promoter, and a tissue preferred promoter.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>A plant cell comprising the construct of claim 2.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>A method for increasing resistance to citrus canker disease in a plant or cell, comprising overexpressing at least one nucleotide sequence set forth in SEQ ID NO: 2-13.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>A method for increasing resistance to citrus canker disease in a plant or cell, comprising
<claim-text>(a) transforming a plant or cell with a construct comprising at least one nucleotide sequence set forth in SEQ ID NO: 2-13, operably linked to a promoter active in plant cells;</claim-text>
<claim-text>(b) regenerating a plant from said transformed plant or cell;</claim-text>
<claim-text>(c) selecting a plant or cell that has increased resistance to citrus canker disease relative to a control plant.</claim-text></claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The method of claim 7, wherein the promoter is a constitutive promoter or a tissues specific promoter.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The method of claim 8, wherein the tissue specific promoter is a xylem-specific promoter, phloem-specific promoter, or a xylem/phloem-specific promoter.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The method of claim 7, wherein the promoter is operably linked to an enhancer.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The method of claim 7, wherein the plant is a member of the Rutaceae family, preferably said plant is selected from the genera of <i>Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia,</i> and <i>Eremocitrus.</i></claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>A plant, plant cell, seed, or fruit produced by the method of claims 6-7.<!-- EPO <DP n="53"> --></claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>A transgenic plant having incorporated into its genome a nucleotide sequence that encodes a disease resistance polypeptide set forth in SEQ IDNO: 15-26.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The transgenic plant of claim 13, wherein the polypeptide is encoded by a nucleotide sequence set forth in SEQ ID NO: 2-13.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>A progeny, fruit, or seed of the plant of claim 14, comprising said nucleotide sequence.</claim-text></claim></claims><drawings mxw-id="PDW16671458" load-source="patent-office"><!-- EPO <DP n="54"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="60" he="162" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="55"> --><figure id="f0002" num="2a,2b,2c,2d"><img id="if0002" file="imgf0002.tif" wi="155" he="151" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="56"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="153" he="124" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="57"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="155" he="129" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="58"> --><figure id="f0005" num="5a,5b,5c,5d"><img id="if0005" file="imgf0005.tif" wi="156" he="136" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="59"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="155" he="137" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="60"> --><figure id="f0007" num="7a,7b,7c"><img id="if0007" file="imgf0007.tif" wi="157" he="140" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
